RAPT Therapeutics (RAPT) Cash & Equivalents: 2020-2023
Historic Cash & Equivalents for Therapeutics (RAPT) over the last 4 years, with Dec 2023 value amounting to $47.5 million.
- Therapeutics' Cash & Equivalents fell 29.99% to $37.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $37.9 million, marking a year-over-year decrease of 29.99%. This contributed to the annual value of $47.5 million for FY2023, which is 21.91% up from last year.
- Per Therapeutics' latest filing, its Cash & Equivalents stood at $47.5 million for FY2023, which was up 21.91% from $38.9 million recorded in FY2022.
- Therapeutics' Cash & Equivalents' 5-year high stood at $47.5 million during FY2023, with a 5-year trough of $24.0 million in FY2021.
- Over the past 3 years, Therapeutics' median Cash & Equivalents value was $38.9 million (recorded in 2022), while the average stood at $36.8 million.
- Per our database at Business Quant, Therapeutics' Cash & Equivalents decreased by 3.58% in 2021 and then spiked by 62.09% in 2022.
- Yearly analysis of 4 years shows Therapeutics' Cash & Equivalents stood at $24.9 million in 2020, then declined by 3.58% to $24.0 million in 2021, then spiked by 62.09% to $38.9 million in 2022, then grew by 21.91% to $47.5 million in 2023.